key: cord-0898735-qb9rsub8
authors: Wu, Jashin J.; Martin, Amylee; Liu, Jeffrey; Thatiparthi, Akshitha; Ge, Shaokui; Egeberg, Alexander; Thyssen, Jacob P.
title: The risk of COVID-19 infection in patients with atopic dermatitis - a retrospective cohort study
date: 2021-10-06
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.09.061
sha: 05fcc088106613e6d5e63c5b179ec9d241e1cbb8
doc_id: 898735
cord_uid: qb9rsub8

nan

The dermatology community remains concerned regarding risk of COVID-19 in individuals with 35 atopic dermatitis (AD). Using Symphony Health derived data from COVID-19 Research 36 Database 1 , we aimed to 1) assess risk of contracting COVID-19 in adults with AD, while 37 controlling for demographic factors and comorbidities, known/speculated to be COVID-19 risk 38 factors, and 2) assess risk of contracting COVID-19 in adults with AD treated with dupilumab. 39 40 Subjects 20 years old, with known ethnicity/race, type of payer, and sex were eligible for 41 inclusion. All subjects, with at least two diagnoses of AD prior to 1/1/2020, were included in the 42 AD cohort. Subjects with no record of AD diagnosis prior to 1/1/2020 were randomly selected in 43 10:1 size ratio (compared to AD group) into the control group. Laboratory confirmed cases of 44 COVID-19 between 1/1/2020 and 4/17/2021 were identified. Description of methodology of this 45 retrospective study is provided in Mendeley supplemental methods. 46 47 39,417 and 397,293 subjects were included in the AD and non-AD cohorts, respectively (Table  48 I). Poisson regression revealed a crude COVID-19 incidence rate ratio (IRR) of 1.41 (95% 49 confidence interval [CI] 1.34-1.48) for adults with AD compared to adults without AD (Table  50 II). After adjusting for demographic factors and baseline comorbidities, the IRR remained 51 statistically significant but was reduced to 1.18 (95% CI 1.12-1.24). 52

In the sensitivity analysis including subjects with missing race/ethnicity, gender, and/or type of 54 payer (to account for selection bias), the risk of COVID-19 associated with AD remained 55 unchanged (adjusted IRR 1.18). In the other sensitivity analysis (to address potential type I error) 56

including subjects aged 20-65 with zip codes in California/New York and excluding subjects 57 with comorbidities associated with COVID-19 (n=32,857), the adjusted IRR point estimate was 58 higher (1.31, 95% CI 1.11-1.53) than the main analysis. 59 60 Dupilumab was associated with lower risk of contracting COVID-19 (adjusted IRR 0.66, 95% CI 61 0.52-0.83) compared to no systemic medication. Additionally, AD subjects on dupilumab 62 showed significantly lower associated risk of contracting COVID-19 infection compared to AD 63 subjects exposed to prednisone, cyclosporine, and/or azathioprine (Table II) . 

Homepage -COVID-19 Research Database

Allergic disorders and susceptibility to and severity 109 of COVID-19: A nationwide cohort study

AD vs no AD -sensitivity analysis 1 1.51 (1.45-1.56)

Dupilumab vs no systemic medication 0

asthma, rhinitis, overweight/obese, congestive heart failure, chronic ischemic heart disease, chronic kidney disease, chronic obstructive pulmonary disease, essential hypertension, human immunodeficiency virus, type-2 diabetes mellitus, type-1 diabetes mellitus) Sensitivity analysis 1 = includes subjects with missing race/ethnicity, type of payor, and/or sex Sensitivity analysis 2 = includes subjects ages 20-59 years old with zip code in California or New York and excludes subjects with history of asthma, rhinitis, overweight/obese, congestive heart failure, chronic ischemic heart disease, chronic kidney disease, chronic obstructive pulmonary disease, essential hypertension

Mendeley supplemental methods

Mendeley supplemental table I. ICD-10 diagnosis codes for 148 defining baseline comorbidities

Mendeley supplemental table II. Summary of medication exposure 151 for subjects with moderate-to-severe atopic dermatitis

Mendeley supplemental figure I. Study timeline and group 154 stratification